Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The purpose of this study is to evaluate the long-term antibody persistence as well as safety of GSK Biologicals\' MenACWY-TT vaccine versus Meningitec up to 6 years after booster vaccination administered in healthy 5 year old children in the study MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (NCT00955682), who were primed with the same vaccine in the study MENACWY-TT-039 (NCT00474266) at 12 through 23 months of age.
Epistemonikos ID: 245d3cb01081a666234f6f4f98c56449231aaf7d
First added on: May 11, 2024